Plain-English translation of NCT06598761 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether adding immunotherapy (using a medication called tirilizumab) and radiation therapy after surgery can help people with advanced upper urinary tract cancer live longer and stay cancer-free. Some patients will receive the new medication plus radiation starting a few weeks after their surgery, while others will be closely monitored without additional treatment, so researchers can see which approach works better.
Advanced cancers of the ureter and kidney's urine-collecting system are serious and often come back after surgery alone. This study wants to know whether this medication combined with radiation can prevent cancer from returning and improve survival in patients who either cannot tolerate or choose not to have chemotherapy.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be placed into one of two groups. One group receives the immunotherapy medication by injection every three weeks for at least one year, along with radiation therapy to the surgical area starting 4–6 weeks after surgery (about 5 weeks of daily treatments). The other group is monitored closely with regular check-ups and imaging but receives no additional treatment after surgery. Both groups will have scheduled follow-up visits to check for cancer recurrence and side effects.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China
Sponsor
Peking University First Hospital
Enrollment target
~60 participants
Started
January 2022
Primary completion
December 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in November 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.